1:38 PM
 | 
May 17, 2018
 |  BC Innovations  |  Emerging Company Profile

Beyond B cells

How Vor Biopharma’s platform could eliminate on-target toxicity for CAR Ts

PureTech Health plc subsidiary Vor Biopharma Inc. plans to combine CAR T therapies with hematopoietic stem cells modified to go unrecognized by CAR Ts. The approach could increase the types of immune cells that can be targeted by this modality for hematologic malignancies and eliminate the on-target toxicities of existing CAR T agents.

PureTech VP Aleks Radovic-Moreno, who is Vor program lead, said tumor-specific targets for CAR T therapies have been difficult to identify, as “antigens are almost always co-expressed on normal cells, or they are very rare, patient-specific and not suitable targets.”

CAR T therapies Kymriah tisagenlecleucel from Novartis AG and Yescarta axicabtagene ciloleucel from Gilead Sciences Inc. both target CD19, an antigen found on both cancerous and healthy B cells.

“Because of the fortuitous biology that allows humans to survive without...

Read the full 645 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$85 USD
More Info >